Michael C. Burger - Concepedia

Author

Michael C. Burger

Also Known As

Burger, M.C., M C Burger, M. Burger, M. C. Burger, M.C. Burger, Michael Burger, Michael C Burger, Michael C. Burger, Michiel Burger

126

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Goethe University Frankfurt German Cancer Research Center Heidelberg University University Hospital Frankfurt Deutschen Konsortium für Translationale Krebsforschung

About

Michael C. Burger is an author at Goethe University Frankfurt specializing in medicine, glioma, and high-grade gliomas.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	876
2	Cell Biology	6	6	201
3	Health Sciences	3	3	99
4	Public Health	1	1	48
5	Cellular Physiology	1	1	17

Michael C. Burger

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate Lukas Bunse, Stefan Pusch, Theresa Bunse, Nature Medicine Cancer ImmunosurveillanceMedicineT-regulatory CellImmunologyTumor Immunity	2018	515
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma Congcong Zhang, Michael C. Burger, Lukas Jennewein, JNCI Journal of the National Cancer Institute	2015	377
Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival Sabrina Genßler, Michael C. Burger, Congcong Zhang, OncoImmunology	2015	186
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma Michael C. Burger, Marie-Thérèse Forster, A Romański, Neuro-Oncology	2023	105
Interference with the HSF1/HSP70/BAG3 Pathway Primes Glioma Cells to Matrix Detachment and BH3 Mimetic–Induced Apoptosis Patrick Antonietti, Benedikt Linder, Stephanie Hehlgans, Molecular Cancer Therapeutics Tumor BiologyTranscription Factor UpstreamVivo Tumor GrowthGliomaMedicine	2016	76
Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease Michael C. Burger, Michael Ronellenfitsch, Nadja I. Lorenz, Oncology Reports	2017	71
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors Antje Wick, Oliver Bähr, Martin Schüler, Clinical Cancer Research	2021	64
Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine Katharina J. Wenger, Marlies Wagner, Se-Jong You, Oncology Letters Neuro-oncologyPfs RateOncologyRadiation TherapyLast-line Treatment	2017	63
Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death Michael Ronellenfitsch, Daniel P. Brucker, Michael C. Burger, Brain Chemoprevention StrategyCell DeathMetabolic RemodelingGliomaTumor Biology	2009	52
AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma Maja Strecker, Karolin Wlotzka, F Straßheimer, OncoImmunology	2022	49

Page 1